Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trials In Review: Big Hits And Misses In 2018

Executive Summary

Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.

You may also be interested in...



BMS Ready To Pounce On Non-Chemo Opportunity In Lung Cancer With Checkmate-227 Data

The Checkmate-227 results surprised with an OS benefit for Opdivo plus Yervoy in first-line NSCLC and a miss for the Opdivo-chemotherapy combination. Bristol reported a solid quarter, with growth for IO, Eliquis.

Merck KGAA/Pfizer's Bavencio Failure Casts More Shade On Immunotherapy For Ovarian Cancer

Phase III first-line JAVELIN Ovarian 100 study fails, but trial combining Bavencio with PARP inhbitor Talzenna in similar setting goes on.

SOLO-3 Adds To AZ/MSD’s Lynparza’s Ovarian Cancer Success Tally But Impact Minimal

Companies plan to discuss SOLO-3 data with the US FDA after Lynparza shows a benefit in third-line ovarian cancer, but commercial impact will be slight.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132281

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel